• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Specific risk scores for specific purposes: use CHA2DS2-VASc for assessing stroke risk, and use HAS-BLED for assessing bleeding risk in atrial fibrillation.

作者信息

Dzeshka Mikhail S, Lip Gregory Y H

机构信息

University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, United Kingdom; Grodno State Medical University, Grodno, Belarus.

University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, United Kingdom; Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

出版信息

Thromb Res. 2014 Aug;134(2):217-8. doi: 10.1016/j.thromres.2014.06.003. Epub 2014 Jun 11.

DOI:10.1016/j.thromres.2014.06.003
PMID:24958223
Abstract
摘要

相似文献

1
Specific risk scores for specific purposes: use CHA2DS2-VASc for assessing stroke risk, and use HAS-BLED for assessing bleeding risk in atrial fibrillation.针对特定目的的特定风险评分：使用CHA2DS2-VASc评估卒中风险，使用HAS-BLED评估房颤出血风险。
Thromb Res. 2014 Aug;134(2):217-8. doi: 10.1016/j.thromres.2014.06.003. Epub 2014 Jun 11.
2
Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial.比较 CHADS2、CHA2DS2-VASc 和 HAS-BLED 评分在预测抗凝治疗的心房颤动患者临床相关出血中的作用：AMADEUS 试验。
Thromb Haemost. 2013 Nov;110(5):1074-9. doi: 10.1160/TH13-07-0552. Epub 2013 Sep 19.
3
The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.在接受抗凝治疗的房颤患者中，HAS-BLED 评分对大出血的预测准确性优于 CHADS2 或 CHA2DS2-VASc 评分。
J Am Coll Cardiol. 2013 Dec 10;62(23):2199-204. doi: 10.1016/j.jacc.2013.08.1623. Epub 2013 Sep 18.
4
The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience.CHADS2和CHA2DS2-VASc评分对房颤出血风险的预测能力：MAQI(2)研究经验
Thromb Res. 2014 Aug;134(2):294-9. doi: 10.1016/j.thromres.2014.05.034. Epub 2014 Jun 2.
5
Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey.心房颤动真实世界患者的卒中与出血风险共分布：欧洲心脏调查
Am J Med. 2014 Oct;127(10):979-986.e2. doi: 10.1016/j.amjmed.2014.05.003. Epub 2014 May 13.
6
Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.评估 182678 例心房颤动患者缺血性卒中和出血的风险分层方案：瑞典心房颤动队列研究。
Eur Heart J. 2012 Jun;33(12):1500-10. doi: 10.1093/eurheartj/ehr488. Epub 2012 Jan 13.
7
Pre-stroke CHADS2 and CHA2DS2-VASc scores are useful in stratifying three-month outcomes in patients with and without atrial fibrillation.中风前 CHADS2 和 CHA2DS2-VASc 评分可用于分层伴有和不伴有心房颤动的患者三个月结局。
Cerebrovasc Dis. 2013;36(4):273-80. doi: 10.1159/000353670. Epub 2013 Oct 16.
8
CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention.CHADS2、CHA2DS2-VASc和HAS-BLED作为接受经皮冠状动脉介入治疗的房颤患者预后的预测指标。
Thromb Res. 2014 Apr;133(4):560-6. doi: 10.1016/j.thromres.2014.01.007. Epub 2014 Jan 11.
9
[Thromboembolic and bleeding risk assessment in patients with non-rheumatic atrial fibrillation using CHA2DS2-VASc and HAS-BLED scoring systems].使用CHA2DS2-VASc和HAS-BLED评分系统对非风湿性心房颤动患者进行血栓栓塞和出血风险评估
Lijec Vjesn. 2013 Mar-Apr;135(3-4):86-91.
10
CHADS₂, CHA₂S₂DS₂-VASc, and long-term stroke outcome in patients without atrial fibrillation.CHADS₂、CHA₂DS₂-VASc 评分与非心房颤动患者的长期卒中结局。
Neurology. 2013 Mar 12;80(11):1009-17. doi: 10.1212/WNL.0b013e318287281b. Epub 2013 Feb 13.

引用本文的文献

1
Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).心房颤动抗凝治疗患者血栓栓塞和出血事件的风险因素：前瞻性、多中心观察性预防血栓栓塞事件-心房颤动欧洲登记研究（PREFER in AF）。
BMJ Open. 2019 Mar 30;9(3):e022478. doi: 10.1136/bmjopen-2018-022478.
2
Aversion to ambiguity and willingness to take risks affect therapeutic decisions in managing atrial fibrillation for stroke prevention: results of a pilot study in family physicians.对模糊性的厌恶和冒险意愿会影响房颤卒中预防治疗决策：家庭医生的一项试点研究结果
Patient Prefer Adherence. 2017 Sep 11;11:1533-1539. doi: 10.2147/PPA.S143958. eCollection 2017.
3
Geriatric Patient Safety Indicators Based on Linked Administrative Health Data to Assess Anticoagulant-Related Thromboembolic and Hemorrhagic Adverse Events in Older Inpatients: A Study Proposal.基于关联行政健康数据的老年患者安全指标，用于评估老年住院患者抗凝相关血栓栓塞和出血不良事件：一项研究提案。
JMIR Res Protoc. 2017 May 11;6(5):e82. doi: 10.2196/resprot.7562.
4
A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC.在直接口服抗凝剂（DOAC）出现之前，关于维生素K拮抗剂与心房颤动相关结局的人群数据库研究。
Br J Clin Pharmacol. 2016 Mar;81(3):569-78. doi: 10.1111/bcp.12807. Epub 2015 Dec 28.